Most Read Articles
Roshini Claire Anthony, 11 Jun 2018

Patients who received a combination of ticagrelor plus aspirin within 24 hours of undergoing coronary artery bypass grafting (CABG) had significantly improved saphenous vein graft patency rates 1 year post-procedure compared with those who only received aspirin, according to findings of the DACAB* trial.

10 Jun 2018
Treatment with rituximab (RTX) is well tolerated and leads to stability or improvement in pulmonary function or severity of interstitial lung disease (ILD) on computed tomography (CT) in most patients, a recent study has shown.
10 Jun 2018
The dual-action antibody directed against epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), duligotuzumab, does not appear to provide survival advantage compared with cetuximab in patients with RAS exon 2/3 wild-type metastatic colorectal cancer treated with the FOLFIRI regimen, according to the results of a phase II trial.
Jairia Dela Cruz, 09 Jan 2017
The sulfonylurea glimepiride may pose an increased risk of hypoglycaemia in a subgroup of elderly type 2 diabetes (T2D) patients with lower β-cell function when added to a metformin regimen, according to a post-hoc analysis of data from the GENERATION* trial.

Product Highlight - Basalog

16 Dec 2016
BASALOG – Insulin glargine (rDNA) 100 IU/mL soln for inj (cartridge) – CCM Pharmaceuticals

A quality alternative of basal insulin for effective HbA1C control:1-4

  • Equivalent to innovator in terms of:1-4
    • Safety: Reduced risk of nocturnal hypoglycemia1-4
    • Efficacy: Long lasting effect for 24 hours blood glucose control1-4
  • Approved in Japan and more than 20 other countries4
  • Does not contain ingredient derived from animal origin4

References:
1. Verma M., Hazra P., Iyer H., et al., Basalog® is similar to Lantus® in producing glycemic control in patients with type 1 diabetes mellitus on multiple daily insulin regimens. Int J Diabetes Dev Ctries. 2011; 31(1):26–31.
2. Biocon S. A., Phase 3 Study of FFP-112 in Patients with Type I Diabetes Under Intensive Insulin Therapy, 2014.
3. Basalog® Package Insert. 4. Data on file, Biocon Limited.

  • Further information is available in section 11b, New In This Issue and mims.com.
    Full prescribing information is available upon request.
  • Related MIMS Drugs

    Digital Edition
    Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
    Sign In To Download
    Editor's Recommendations
    Most Read Articles
    Roshini Claire Anthony, 11 Jun 2018

    Patients who received a combination of ticagrelor plus aspirin within 24 hours of undergoing coronary artery bypass grafting (CABG) had significantly improved saphenous vein graft patency rates 1 year post-procedure compared with those who only received aspirin, according to findings of the DACAB* trial.

    10 Jun 2018
    Treatment with rituximab (RTX) is well tolerated and leads to stability or improvement in pulmonary function or severity of interstitial lung disease (ILD) on computed tomography (CT) in most patients, a recent study has shown.
    10 Jun 2018
    The dual-action antibody directed against epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), duligotuzumab, does not appear to provide survival advantage compared with cetuximab in patients with RAS exon 2/3 wild-type metastatic colorectal cancer treated with the FOLFIRI regimen, according to the results of a phase II trial.
    Jairia Dela Cruz, 09 Jan 2017
    The sulfonylurea glimepiride may pose an increased risk of hypoglycaemia in a subgroup of elderly type 2 diabetes (T2D) patients with lower β-cell function when added to a metformin regimen, according to a post-hoc analysis of data from the GENERATION* trial.